Format

Send to

Choose Destination
See comment in PubMed Commons below
Tremor Other Hyperkinet Mov (N Y). 2014 Apr 14;4:223. doi: 10.7916/D8PN93NZ. eCollection 2014.

HD-PRO-TRIAD™ Validation: A Patient-reported Instrument for the Symptom Triad of Huntington's Disease.

Author information

1
University of Michigan, Ann Arbor, Michigan, United States of America.
2
Northwestern University, Evanston, Illinois, United States of America.
3
University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
4
Analysis Group, Inc., Boston, Massachusetts, United States of America.
5
New York University Langone Medical Center, New York, New York, United States of America ; Kessler Foundation, West Orange, New Jersey, United States of America.
6
Lundbeck LLC, Deerfield, Illinois, United States of America.
7
Boston University School of Medicine, Boston, Massachusetts, United States of America.

Abstract

BACKGROUND:

Few valid, disease-specific measures of health-related quality of life (HRQOL) capture the spectrum of symptoms associated with Huntington's disease (HD). The HD-PRO-TRIAD™ is a new, HD-specific, patient-reported outcome (PRO) instrument of the HD symptom triad (cognitive decline, emotional/behavioral dyscontrol, and motor dysfunction) designed for clinical research and practice. The objective was to validate the HD-PRO-TRIAD™ through a cross-sectional sample of individuals with HD and caregivers.

METHODS:

Development of the HD-PRO-TRIAD™ has been described elsewhere. A total of 132 individuals with HD and 40 HD caregivers, comprising 29 dyads, participated in the cross-sectional psychometric validation of this instrument. Participants provided responses to the HD-PRO-TRIAD™ and other HRQOL and disease severity instruments (EuroQOL 5D, Short Form 12, Neuro-QOL Item Banks, PROMIS Global Health, and self-reported Unified Huntington's Disease Rating Scale Total Functional Capacity and Independence Scales). Internal consistency, construct validity, and patient-caregiver proxy consistency were evaluated.

RESULTS:

Internal consistency of the three domains and overall HD-PRO-TRIAD™ instrument was supported by Cronbach's alpha values ≥0.94. Construct validity was supported by significant correlations between HD-PRO-TRIAD™ domain scores and other measures of the same domains (e.g., significant positive correlations between HD-PRO-TRIAD™ Anxiety with Neuro-QOL Anxiety), as well as slightly weaker but still strong correlations with other HRQOL instruments (e.g., HD-PRO-TRIAD™ Anxiety and UHDRS Independence; all p<0.01). Consistency between patient self-report and caregiver proxy report was supported by an intra-class correlation coefficient ≥0.92 for all three domains and the overall instrument.

DISCUSSION:

These data indicate that HD-PRO-TRIAD™ is a reliable and valid HRQOL instrument that captures the typical triad of HD symptoms.

KEYWORDS:

HD-PRO-TRIAD™; Huntington's disease; health-related quality of life; patient-reported outcome; psychometric validation; quality-of-life scale

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Center for Digital Research and Scholarship, Columbia University Icon for PubMed Central
    Loading ...
    Support Center